After receiving a torrent of data about
#semaglutide and newer
#ObesityMedicines at
#ADA2024, we're left wondering. Is semaglutide becoming old news or is it only now hitting its stride?
#ADASciSessionshttps://conscienhealth.org/2024/06/semaglutide-at-ada2024-old-news-or-gaining-momentum/
Semaglutide at ADA2024: Old News or Gaining Momentum? - ConscienHealth
As we head home from the ADA meeting in Orlando, we wonder. Is semaglutide fast becoming old news or is it gaining momentum?
At
#ADA2024, it's plain that the top 3 problems for
#ObesityCare are scale, scale, and scale. It stems from inequitable systems, exorbitant pricing, and Inadequate supply that sum to poor
#AccessToCare.
#ADASciSessionshttps://conscienhealth.org/2024/06/ada2024-where-is-the-problem-with-scale-for-obesity-care/
ADA2024: How Big Is the Problem with Scale for Obesity Care? - ConscienHealth
At ADA2024, it is obvious that the need for obesity care is great and that adequate scale for delivering that care is our biggest challenge.
New data at
#ADA2024 tells us that even low-dose, brief exposure to
#BPA causes
#InsulinResistance to rise. While many folks are busy demonizing food, BPA seems to get a pass from FDA.
#ADASciSessions https://conscienhealth.org/2024/06/ada-2024-bpa-causes-insulin-resistance-why-do-we-drink-it/
ADA 2024: BPA Causes Insulin Resistance. Why Do We Drink It? - ConscienHealth
A new study at ADA2024 demonstrates that BPA, even in brief exposure at low doses, causes insulin resistance to rise. FDA should act.
ConscienHealth